Markets
Borrow
Earn
Invest
Private
Security
Newsroom
More
Log In
Sign Up
Markets
Market Overview
Indices and commodities.
Digital Credit
Bitcoin treasury preferreds.
AI Stocks
The artificial intelligence theme.
Bitcoin Treasuries
Companies holding bitcoin.
Economy
Sectors, global markets and rates.
Popular Portfolios
13F filings, smart money.
Borrow
Borrow
Borrow USDT or USDC against your BTC without giving it up.
ReFi
Switch your bitcoin-backed loan and pay less interest.
Earn
Carry Trade
Borrow, invest, keep the spread.
Stock Dividends
Dividends from tokenized equities.
Invest
Private
Security
Newsroom
More
Company
About Us
Our leadership team, mission, and investors.
Whitepaper
Vision, purpose, and architecture behind Roxom.
Legal
Terms, privacy, and disclosures.
Resources
Help Center
Guides, FAQs & support.
Rulebook
Trading logic, platform rules, and fundamentals.
API Docs
Connect, authenticate, and build with our API.
Status
Current platform health and incidents.
Chart
Financials
Earnings
News
About
Dividends
Insider
Filings
BTC
SATS
USD
1d
1w
1m
6m
YTD
1y
5y
All
Loading chart
1 BTC
=
- USD
BTC
SATS
Loading market data...
Chart
Financials
Earnings
News
About
Dividends
Insider
Filings
BTC
SATS
USD
1d
1w
1m
6m
YTD
1y
5y
All
Loading chart
CL
ClearPoint Neuro, Inc. Common Stock
CLPT
Mkt Cap
$276.8M
Volume
843.46K
Next Earnings
October 28th
Chart
Financials
Earnings
News
About
Dividends
Insider
Filings
BTC
SATS
USD
1d
1w
1m
6m
YTD
1y
5y
All
Loading chart
CL
CLPT
CL
ClearPoint Neuro, Inc. Common Stock
CLPT
News
·
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ClearPoint Neuro, Inc. - CLPT
Mkt Cap
$294.1M
Volume
843.46K
Next Earnings
October 28th
Chart
Financials
Earnings
News
About
Insider
Filings
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ClearPoint Neuro, Inc. - CLPT
Pomerantz LLP is investigating potential securities fraud claims against ClearPoint Neuro following a significant stock price decline. On September 29, 2026, development partner uniQure announced that their joint treatment for Huntington's disease failed to achieve statistical significance on a primary clinical measure at 48 months, causing ClearPoint's stock to plummet 23.12% to $11.77 per share.
GlobeNewswire Inc. · Oct 13, 2026
AngioDynamics (ANGO) Reports Q1 Loss, Lags Revenue Estimates
AngioDynamics reported a quarterly loss of $0.04 per share, beating consensus estimates of $0.10 loss by 60%, but missed revenue expectations with $80.92 million versus the estimated $81.85 million. The medical device company has a Zacks Rank #3 (Hold) rating with mixed estimate revisions. The Medical-Instruments industry ranks in the top 39% of Zacks industries.
Zacks Investment Research · Oct 8, 2026
Global MRI Guided Neurosurgical Ablation Market Poised for Steady Growth, Projected to Reach USD 227.56 Million by 2034 Driven by Growing Adoption and Advancements in Non-Cooled Laser Systems: FMI
The global MRI-guided neurosurgical ablation market is expected to grow significantly, reaching a value of USD 227.56 million by 2034, driven by advancements in technology, regulatory approvals, and enhanced healthcare accessibility.
GlobeNewswire Inc. · Nov 20, 2024
ClearPoint Neuro Congratulates Partner Aspen Neuroscience on Use of the ClearPoint® Navigation System for All Enrolled Patients in ASPIRO Clinical Trial
ClearPoint® Navigation System to be used for all enrolled patients in Aspen's ASPIRO Parkinson's cell therapy clinical trial
GlobeNewswire Inc. · Jun 20, 2024
ClearPoint's (CLPT) New Products to Boost Neurosurgical Segment
ClearPoint (CLPT) announces the full market release of the SmartFrame OR platform, intended for performing DBS, and Prism Neuro Laser Therapy System for providing thermal therapy.
Zacks Investment Research · Jun 3, 2024
ClearPoint Neuro Announces Full Market Release of SmartFrame OR™ and ClearPoint PRISM® 3T Laser Therapy System
Newly Launched ClearPoint Neuro technology - SmartFrame OR and Prism Laser will be on display at ASSFN in Nashville from June 1 - 4
GlobeNewswire Inc. · Jun 1, 2024
Does ClearPoint Neuro (CLPT) Have the Potential to Rally 81.49% as Wall Street Analysts Expect?
The consensus price target hints at an 81.5% upside potential for ClearPoint Neuro (CLPT). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Zacks Investment Research · May 29, 2024
Wall Street Analysts Predict a 70.65% Upside in ClearPoint Neuro (CLPT): Here's What You Should Know
The mean of analysts' price targets for ClearPoint Neuro (CLPT) points to a 70.7% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Zacks Investment Research · May 13, 2024
Rapid Micro Biosystems, Inc. (RPID) Reports Q1 Loss, Tops Revenue Estimates
Rapid Micro Biosystems (RPID) delivered earnings and revenue surprises of -6.90% and 0.74%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Zacks Investment Research · May 3, 2024
Tandem Diabetes Care, Inc. (TNDM) Reports Q1 Loss, Tops Revenue Estimates
Tandem Diabetes Care (TNDM) delivered earnings and revenue surprises of 21.25% and 10.76%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Zacks Investment Research · May 2, 2024
Holdings
Open Orders (0)
Positions (0)
Order History
Dividends
Transfers
Log In
to start trading
CL
CLPT
ClearPoint Neuro, Inc. Common Stock
Buy
Sell
Market
Limit
Soon
CLPT
25%
50%
75%
Max
Pay with
—
Start Trading
Available Balance
0.00
Your Position
You don't own any CLPT yet.
Related Tickers
Earnings